Ceryvyn Therapeutics (ASX:CYV) Debt-to-Equity: 0.00 (As of Jun. 2025)


What is Ceryvyn Therapeutics Debt-to-Equity?

Ceryvyn Therapeutics ASX:CYV -7.69% Debt-to-Equity is 0.00 as of Jun. 2025. The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 103626.84% on this metric.

Ceryvyn Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was A$0.00 Mil. Ceryvyn Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was A$0.00 Mil. Ceryvyn Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2025 was A$-308.84 Mil. Ceryvyn Therapeutics's debt to equity for the quarter that ended in Jun. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ceryvyn Therapeutics's Debt-to-Equity or its related term are showing as below:

ASX:CYV' s Debt-to-Equity Range Over the Past 10 Years
Min: -14.67   Med: -0.93   Max: 0
Current: -0.8
ASX:CYV's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs ASX:CYV: -0.80

Ceryvyn Therapeutics  (ASX:CYV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ceryvyn Therapeutics Debt-to-Equity Related Terms

Ceryvyn Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Debt-to-Equity Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -14.67 -1.87 0.00

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.67 -0.00 -1.87 -0.93 0.00

ASX:CYV vs VRTX, REGN, ALNY: Debt-to-Equity Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Debt-to-Equity falls into.


Ceryvyn Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ceryvyn Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -308.842
=0.00

Ceryvyn Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -308.842
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Ceryvyn Therapeutics (ASX:CYV) has a Debt-to-Equity of 0.00 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 965 companies in the Biotechnology industry.
Is Ceryvyn Therapeutics' Debt-to-Equity too high?
Ceryvyn Therapeutics' current Debt-to-Equity is 0.00. Based on the distribution chart, Ceryvyn Therapeutics ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 965 companies for Debt-to-Equity. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Debt-to-Equity is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.